Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

BACKGROUND: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (RCT), sarilumab + methotrexate (MTX) treatment resulted in clinical improvements at 24 weeks that were maintained at 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Kosinski, Mark, Chen, Chieh-I, Joseph, George, Rendas-Baum, Regina, Graham, Neil M. H., van Hoogstraten, Hubert, Bayliss, Martha, Fan, Chunpeng, Huizinga, Tom, Genovese, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012017/
https://www.ncbi.nlm.nih.gov/pubmed/27600829
http://dx.doi.org/10.1186/s13075-016-1096-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012017/
https://www.ncbi.nlm.nih.gov/pubmed/27600829
http://dx.doi.org/10.1186/s13075-016-1096-9

Ejemplares similares